SEARCH

SEARCH BY CITATION

  • PATTERNS OF PROGRESSION IN PATIENTS WITH V600 BRAF-MUTATED MELANOMA METASTATIC TO THE BRAIN TREATED WITH DABRAFENIB (GSK2118436)

    M. Azer, A. Menzies, L. Haydu, R. Kefford, G. Long

  • BEVACIZUMAB IN ADDITION TO CHEMOTHERAPY IN THE TREATMENT OF RELAPSED OVARIAN CANCER: NORTHERN SYDNEY GYNAECOLOGICAL-ONCOLOGY UNIT EXPERIENCE

    S. Baron-Hay, J. McLachlan

  • THE OUTLIERS OF PANCREATIC CANCER: PRELIMINARY DATA FOR TIMELESS EXPRESSION AS A PROGNOSTIC BIOMARKER

    L. Chantrill, A. Gill, A. Johns, J. Wu, C. Scarlett, A. Biankin, Australian Pancreatic Cancer Genome Initiative

  • CHEMOTHERAPY TOXICITY AND COMPLIANCE AMONGST INDIGENOUS AUSTRALIANS DIAGNOSED WITH CANCER

    M. Charakidis, M. Okera, N. Karanth

  • INDIVIDUALISED MEASUREMENT OF TUMOUR-DERIVED CIRCULATING DNA IN PATIENTS WITH PANCREATIC CANCER: A MARKER OF PROGNOSIS AND THERAPEUTIC RESPONSE

    V.T. Chin, N. Waddell, K. Nones, K. Quek, A. Mawson, A. Johns, Australian Pancreatic Cancer Genome Initiative, S. Grimmond, A. Biankin

  • AN ELEVATED NEUTROPHIL-LYMPHOCYTE RATIO PREDICTS SURVIVAL IN METASTATIC NON SMALL CELL LUNG CANCER

    T.D. Clay, W. Chua, M.M. Moore

  • STAGING FDG PET PREDICTS SURVIVAL IN GASTRIC CANCER AND ITS POTENTIAL IMPACT ON MANAGEMENT DECISIONS

    N. Coupe, D. Karikios, N. Merrett, M. Lin

  • PAIN IN PATIENTS WITH METASTATIC BREAST CANCER: RESULTS FROM A PHASE III TRIAL OF DENOSUMAB VERSUS ZOLEDRONIC ACID

    R.H. de Boer, A. Stopeck, L. Fallowfield, D. Patrick, C.S. Cleeland, G.G. Steger, Y. Qian, R.D. Dansey, A.H. Braun, K. Chung

  • DENOSUMAB IN PATIENTS WITH BREAST CANCER AND BONE METASTASES PREVIOUSLY TREATED WITH ZOLEDRONIC ACID OR DENOSUMAB: A PRE-SPECIFIED TWO YEAR OPEN-LABEL EXTENSION TREATMENT PHASE OF A PIVOTAL PHASE III STUDY

    R.H. de Boer, A.T. Stopeck, A. Lipton, M. Martín, J.-J. Body, A. Paterson, G.G. Steger, K. Tonkin, Y. Fujiwara, D. Yardley, J. Jassem, T. Takano, P. Solal-Celigny, M. Fan, A. Braun

  • MULTI-TARGETED MOLECULAR PROFILING OF ADVANCED REFRACTORY SOLID TUMOUR CANCERS: INFLUENCE ON TREATMENT CHOICE AND OUTCOMES

    A. Dean, N. Zeps

  • IDENTIFYING AND PRIORITISING GAPS IN COLORECTAL CANCER TRIALS RESEARCH IN AUSTRALIA

    R. Dear, A. Barratt, A. Evans, M. Tattersall, J. Simes, J. Newsom, D. Kent, S. Crossing, C. Holliday, E. Segelov, G. Hruby

  • PATIENTS' AND HEALTH PROFESSIONALS' PERSPECTIVES ON THE OUTCOMES AND CONDUCT OF MULTIDISCIPLINARY CANCER MEETINGS

    B. Devitt, J. Philip, M. Singh, L. Mileshkin, S. McLachlan

  • SAFETY OF BEVACIZUMAB USED IN ROUTINE PRACTICE IN PATIENTS WITH METASTATIC COLORECTAL CANCER

    M. Dzienis, A. Malczewski, J. Goh, B. Hughes, M. Eastgate, D. Wyld, M. Burge

  • MALIGNANT GLIOMA IN REGIONAL AND RURAL COMMUNITIES: COMMUNICATION, EDUCATION AND NEEDS

    K. Field, M. Fleet, N. Guyatt, K. Drummond, M. Rosenthal

  • UNDERSTANDING WHO CAN DRIVE AND WHO SHOULD MAKE THE DECISION: A SURVEY OF GLIOMA PATIENTS AND THEIR DOCTORS

    K. Field, N. Guyatt, M. Fleet, M. Rosenthal, K. Drummond

  • PRESCRIBING PATTERNS FOR BEVACIZUMAB IN FIRST-LINE METASTATIC COLORECTAL CANCER: EXPLORING THE INTRODUCTION OF A NEW DRUG INTO ROUTINE CLINICAL PRACTICE

    K. Field, S. Kosmider, J. McKendrick, D. Yip, S. Parakh, M. Burge, K. Moore, J. Shapiro, L. Nott, M. Wuttke, P. Parente, S. Bae, P. Gibbs

  • PATTERNS OF CARE ACCORDING TO TREATMENT INTENT FOR METASTATIC COLORECTAL CANCER: A REVIEW OF ROUTINE PRACTICE

    K. Field, J. Shapiro, D. Yip, Z. Otty, M. Burge, A. Sharma, L. Lim, L. Lipton, G. Stefanou, J. Desai, J. Tie, P. Gibbs

  • CONCOMITANT CYP2D6 INHIBITOR USE AND PLASMA METABOLITE LEVELS IN BREAST CANCER PATIENTS TREATED WITH TAMOXIFEN

    P. Fox, B. Balakrishnar, A. Menzies, C. Liddle, S. Coulter, P. Provan, V. Gebski, R. Hui, R. Kefford, N. Wilcken, R. Balleine, H. Gurney

  • PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MODAFINIL FOR FATIGUE IN PATIENTS TREATED WITH DOCETAXEL-BASED CHEMOTHERAPY

    E. Hovey, P. de Souza, G. Marx, P. Parente, T. Rapke, A. Hill, A. Bonaventura, A. Michele, P. Kraft, A. Lloyd

  • C-MYB AS A PROGNOSTIC MARKER IN BREAST CANCER AND ITS ROLE IN DEFINING SUB-GROUPS WITH POOR OVERALL SURVIVAL

    M. Iddawela, R. Ali, F. Blows, P. Pharoah, H. Earl, C. Caldas

  • INTEGRATIVE ANALYSIS OF COPY NUMBER AND GENE EXPRESSION USING FFPE CORE BIOPSY TISSUE: FEASIBILITY STUDY

    M. Iddawela, O. Rueda, H. Earl, C. Caldas

  • TO STUDY THE OUTCOMES OF NON SMALL CELL LUNG CANCER AT A REGIONAL CANCER CARE CENTRE IN AUSTRALIA

    H. Jan, K.P. Briscoe

  • EVALUATION OF PATIENT DEMOGRAPHICS, TUMOUR TYPE AND STAGING, AMONGST INDIGENOUS AUSTRALIANS DIAGNOSED WITH SOLID TUMOURS IN THE NORTHERN TERRITORY

    N. Karanth, M. Charakidis, M. Okera

  • EFFICACY OF SEASONAL INFLUENZA VACCINE IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY

    R. Kumar, D. Gordon, C. Karapetis, B. Koczwara, G. Kichendasse, S. Sukumaran

  • CANCER PATIENT'S PERSPECTIVES ON THE USE OF THEIR TUMOUR TISSUE FOR MEDICAL RESEARCH

    R. Kumar, S. Sukumaran, B. Koczwara, G. Kichenadasse, D. Dua, H. Takhar, A. Richards, K. Mead, M. Ly, T. Quek, C. Karapetis

  • CORRELATES OF FEVER IN PATIENTS RECEIVING COMBINED DABRAFENIB (GSK2118436) AND TRAMETINIB (GSK1120212) FOR V600 BRAF-MUTANT METASTATIC MELANOMA

    C. Lee, A. Menzies, L. Haydu, R. Kefford, A. Clements, G. Long

  • TREATMENT OPTIONS FOR STAGE I SEMINOMA POST-ORCHIDECTOMY

    J. Lewin, A. Haydon, J. McKendrick, J. Millar, J. Shapiro, M. Schwarz

  • PERI-OPERATIVE CHEMOTHERAPY IMPROVES RELAPSE-FREE SURVIVAL FOR UROTHELIAL CARCINOMA OF THE BLADDER TREATED BY RADICAL CYSTECTOMY, BUT REMAINS UNDER-UTILISED IN AN AUSTRALIAN TERTIARY REFERRAL INSTITUTION

    M.S. Liew, A. Tafreshi, R. Eapen, I.D. Davis, S. Sengupta

  • TUMOUR:NODE RATIO IN NODE-POSITIVE, NON-METASTATIC BREAST CANCER

    S. Lim, J. Descallar, P. Sayaloune, G. Delaney, G. Papadatos, P. de Souza

  • PATTERNS OF CARE FOR PATIENTS WITH ADVANCED OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER: A RETROSPECTIVE AUDIT

    E. Lin, C. Lo, G. Richardson

  • LEARNING TO BE AN ADVANCED TRAINER

    M. Links

  • NAB-PACLITAXEL SALVAGE CHEMOTHERAPY FOR METASTATIC OCULAR MELANOMA

    S. Lumba, A. Guminski, A. Lee, R. Maher

  • DENOSUMAB PROLONGS BONE-METASTASIS-FREE SURVIVAL IN MEN WITH NON-METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PRESENTING WITH AGGRESSIVE PROSTATE-SPECIFIC ANTIGEN KINETICS: A POST HOC SUBSET ANALYSIS

    G.M. Marx, M.R. Smith, F. Saad, N.D. Shore, S. Oudard, K. Miller, B. Tombal, P. Sieber, K. Fizazi, P.J. Van Veldhuizen, R. Damião, J. Morote, A. Feng, R. Dansey, C. Goessl

  • IMPACT OF AN ONCOLOGY PHARMACIST ATTENDANCE AT A MULTIDISCIPLINARY LUNG CLINIC

    L. Mileshkin, C. Walter, C. Rice, D. Ball, M. Duffy, S. Kirsa, D. Mellor

  • ADJUVANT CHEMOTHERAPY IS EFFECTIVE IN ELDERLY PATIENTS WITH RESECTED PANCREATIC CANCER

    A.M. Nagrial, D.K. Chang, A.L. Johns, L.A. Chantrill, V.T. Chin, A.V. Biankin for the Australian Pancreatic Cancer Network

  • CHOLECYSTITIS AS A COMPLICATION OF HEPATIC IMPLANTATION OF RADIOACTIVE YTTRIUM RESIN MICROSPHERES FOR METASTATIC CANCER

    S. Parakh, S. Gananahda, R. Allen, D. Yip

  • ADJUVANT CHEMOTHERAPY FOLLOWING NEO-ADJUVANT CHEMO-RADIATION FOR RECTAL CANCER IN ONE NEW ZEALAND ONCOLOGY CENTRE

    S. Prince, H. Winter, P. Dixon, S. Kirkwood, C. Hardie

  • RETROSPECTIVE REVIEW OF PATIENTS MANAGED WITH CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER AT THE PRINCESS ALEXANDRA HOSPITAL

    C. Ryan, V. Atkinson, K. Klein

  • FIVE YEARS OF TELEONCOLOGY IN NORTH QUEENSLAND: A SUSTAINABLE MODEL

    S. Sabesan, A. Joshi

  • TREATMENT OF METASTATIC NEUROENDOCRINE TUMOURS WITH 177LUߝOCTREOTATE: EXPERIENCE AT ROYAL BRISBANE AND WOMEN'S HOSPITAL

    A. Sharma, M. Burge, D. MacFarlane, H. McDade, S. Kemp, D. Wyld

  • PREVENTION OF HYPERCALCAEMIA OF MALIGNANCY IN CANCER PATIENTS WITH METASTATIC BONE DISEASE: A POST-HOC ANALYSIS OF THE EFFECT OF DENOSUMAB TREATMENT

    A. Spencer, I.J. Diel, J.-J. Body, A. Stopeck, S. Vadhan-Raj, G.G. Steger, R. von Moos, F. Goldwasser, A. Feng, A. Braun

  • EFFICACY OF SORAFENIB IN ADVANCED RENAL CELL CARCINOMA INDEPENDENT OF PRIOR TREATMENT, HISTOLOGY OR PROGNOSTIC GROUP

    A. Tafreshi, E. Thientosapol, M.S. Liew, Y. Guo, M. Quaggiotto, M. Boyer, I.D. Davis

  • INTRAPERICARDIAL CHEMOTHERAPY FOR MALIGNANT PERICARDIAL EFFUSION: SYSTEMIC REVIEW

    H. Takhar, K. Khow, D. Dua, B. Koczwara, G. Kichenadasse, C. Karapetis

  • PULMONARY EMBOLISM IN MEDICAL ONCOLOGY PATIENTS: SYMPTOMATIC VERSUS INCIDENTAL

    D.A. Thaker, J. Blazak, D. Wyld, K. Steinke, B. Hughes, M. Burge

  • AN EXPLORATORY ANALYSIS OF THE LONGITUDINAL RELATIONSHIP BETWEEN PROSTATE SPECIFIC ANTIGEN AND THE INFLAMMATORY MARKERS C-REACTIVE PROTEIN AND ERYTHROCYTE SEDIMENTATION RATE

    E. Thientosapol, M. Nelson, J. Descallar, P. de Souza

  • HER-2 POSITIVE BREAST CANCER: SHOULD SIZE INFLUENCE ADJUVANT MANAGEMENT?

    A. Tognela, K. Mok

  • IMPROVED CLINICAL OUTCOMES IN METASTATIC COLORECTAL CANCER PATIENTS ON FIRST-LINE CHEMOTHERAPY WITH BEVACIZUMAB CAN BE PREDICATED BY EARLY RISE IN BLOOD PRESSURE

    N. Upanal, S. Ackland, A. Bonaventura, P. McElduff

  • COGNITIVE FUNCTION AND FATIGUE IN COLORECTAL CANCER PATIENTS: A PROSPECTIVE, LONGITUDINAL CONTROLLED STUDY

    J. Vardy, H. Dhillon, G. Pond, S. Rourke, W. Xu, C. Renton, A. Dodd, P. Beale, S. Clarke, P. Tannock

  • IS TUMOUR HER-2 STATUS A PROGNOSTIC FACTOR IN GASTRIC AND OESOPHAGEAL CANCERS? A SYSTEMATIC REVIEW

    R. Venkateswaran, B. Adelstein, M. Falster, R. Ward

  • DENOSUMAB FOR RESISTANT HYPERCALCAEMIA IN METASTATIC PARATHYROID CARCINOMA

    A. White, S. Bowyer, D. Ransom, A. Davidson

  • BONE METASTASIS-FREE SURVIVAL IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH DENOSUMAB: SUB-GROUP ANALYSES FROM A PHASE III RANDOMISED, DOUBLE BLIND TRIAL

    S. Wong, M. Smith, S. Oudard, L. Karsh, B. Egerdie, P. Van Veldhuizen, F. Gómez-Veiga, D. Dearnaley, L. Dogliotti, H. Fisher, M. Wirth, V. Charu, F. Kueppers, L. Montes de Oca, R. Rendon, I. Pavlik, P.K. Julka, Z. Ye, R. Dansey, C. Goessl